Paper Title
The NALCAM study: efficacy, tolerability, outcome
Keywords
- Alcohol Addiction
- Relapse Prevention
- Naltrexone
- Acamprosate
- Craving
- Alcoholism Treatment
- Pharmacotherapy
- Abstinence Maintenance
- Double-Blind Trial
- Placebo-Controlled
- Detoxified Alcohol Addicts
- Outpatient Treatment
- Treatment Efficacy
- 12-Week Follow-Up
- 24-Week Treatment Effects
- Combination Therapy
- Alcohol Abuse
- Substance Abuse
- Treatment Tolerability
- Craving Reduction
- Alcohol Dependence
- Addiction Recovery
- Relapse Prevention Strategies
- Clinical Trial
- Long-Term Treatment Effects
Journal
Research Impact Tools
Publication Info
Volume: 49 | Issue: 6 | Pages: 342-351
Published On
January, 2003
Downloads
Abstract
Aim: Evaluation of the efficacy and tolerability of Naltrexone and acamprosate, alone or in combination, in the prevention of relapse during 12 weeks of alcoholism treatment and follow-up. </P><P>Method: The study was a double-blind, placebo-controlled trial that included 160 detoxified alcohol addicts. During a 12- week outpatient treatment program, patients received naltrexone or acamprosate or both or placebo. Treatment effects were analysed after 12 and 24 weeks. </P><P>Results: Treatment with naltrexone, acamprosate, or both was significantly more effective than treatment with placebo in maintaining abstinence. The combined treatment was superior to the treatment with acamprosate alone. During the 12-week follow-up, positive treatment effects remained stable. </P><P>Conclusion: Results support the efficacy and tolerability of pharmacotherapy with naltrexone and acamprosate alone or in combination in the prevention of relapse to alcohol abuse.
View more »